Clinical Trial Update: Tagraxofusp and Azacitidine With Venetoclax in Newly Diagnosed Secondary AML After Hypomethylating Agents [Phase 2]

View source ↗

Summary

Phase 2 clinical trial update evaluating the triple combination of Tagraxofusp, Azacitidine, and Venetoclax in newly diagnosed secondary acute myeloid leukemia …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Myeloid Leukemia

Drugs mentioned

• AZACITIDINE (AZACITIDINE)
• Tagraxofusp (tagraxofusp)
• Venetoclax (venetoclax)

Snippet

Sponsor: Joshua Zeidner | Conditions: Acute Myeloid Leukemia | Phase 2 | Status: RECRUITING